Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: A proof-of-concept study

European Journal of Heart Failure

Volumn 16, Issue 9, 2014, Pages 977-983

  Gronda, Edoardo ^a   Seravalle, Gino ^b   Brambilla, Gianmaria ^b   Costantino, Giuseppe ^a   Casini, Andrea ^a   Alsheraei, Ali ^a   Lovett, Eric G ^c   Mancia, Giuseppe ^b   Grassi, Guido ^a,b  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c CVRX INC   (United States)

Author keywords

Baroreflex; Heart failure; Non pharmacological therapy; Sympathetic nervous system

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; POTASSIUM; THIAZIDE DIURETIC AGENT;

AGED; ANEMIA; ARTICLE; BAROREFLEX ACTIVATION THERAPY; CAROTID SINUS PRESSORECEPTOR REFLEX; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DEVICE SAFETY; DEVICE THERAPY; DIURETIC THERAPY; ELECTROSTIMULATION THERAPY; EMERGENCY WARD; FEMALE; FUNCTIONAL STATUS; HEART BEAT; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTABLE CAROTID SINUS STIMULATOR; LENGTH OF STAY; MALE; MUSCLE SYMPATHETIC NERVE ACTIVITY; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OPEN STUDY; PULSE GENERATOR; QUALITY OF LIFE; SINGLE BLIND PROCEDURE; WALKING; ADRENERGIC SYSTEM; CARDIAC RESYNCHRONIZATION THERAPY; CONTROLLED STUDY; FOLLOW UP; HEMODYNAMICS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSORECEPTOR REFLEX; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; BAROREFLEX; CARDIAC RESYNCHRONIZATION THERAPY; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; PROSPECTIVE STUDIES; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84908242972     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.138     Document Type: Article

References (37)

1. Porter TR, Eckberg DL, Fritsch JM, Rea RF, Beightol LA, Schmedtje JF Jr, Mohanty PK. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations. J Clin Invest 1990;85:1362-1371.
2. Benedict CR, Johnstone DE, Weiner DH, Bourassa MG, Bittner V, Kay R, Kirlin P, Greenberg B, Kohn RM, Nicklas JM, McIntyre K, Quinones MA, Yusuf S. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994;23:1410-1420.
3. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-621.
4. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995;92:3206-3211.
5. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlöf G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986;73:913-919.
6. Ferguson DW, Abboud FM, Mark AL. Selective impairment of baroreflex-mediated vasoconstrictor responses in patients with ventricular dysfunction. Circulation 1984;69:451-460.
7. Grassi G, Seravalle G, Bertinieri G, Turri C, Stella ML, Scopelliti F, Mancia G. Sympathetic and reflex abnormalities in heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Clin Sci (Lond) 2001;101:141-146.
8. Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003;42:873-877.
9. Grassi G, Seravalle G, Quarti-Trevano F, Scopelliti F, Dell'Oro R, Bolla G, Mancia G. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension 2007;49:535-541.
10. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
11. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-1736.
12. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136-1143.
13. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN. Effect of valsartan added to background of ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6:937-945.
14. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997;96:1173-1179.
15. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012;6:152-158.
16. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012;6:270-276.
17. Wustmann K, Kucera JP, Scheffers I, Mohaupt M, Kroon AA, de Leeuw PW, Schmidli J, Allemann Y, Delacrétaz E. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009;54:530-536.
18. Sabbah HN. Baroreflex activation for the treatment of heart failure. Curr Cardiol Rep 2012;14:326-333.
19. Zucker IH, Hackley JF, Cornish KG, Hiser BA, Anderson NR, Kieval R, Irwin ED, Serdar DJ, Peuler JD, Rossing MA. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007;50: 904-910.
20. Brandt MC, Madershahian N, Velden R, Hoppe UC. Baroreflex activation as a novel therapeutic strategy for diastolic heart failure. Clin Res Cardiol 2011;100:249-251.
21. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009;54:375-385.
22. Grassi G, Bolla G, Quarti-Trevano F, Arenare F, Brambilla G, Mancia G. Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 2008;10:1186-1191.
23. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993;88:136-145.
24. Kienbaum P, Peters J. Muscle sympathetic baroreflex sensitivity is different at rest and during evoked hypotension. Basic Res Cardiol 2004;99:152-158.
25. Floras JS. Arterial baroreceptor and cardiopulmonary reflex control of sympathetic outflow in human heart failure. Ann NY Acad Sci 2001;940:500-513.
26. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997;96: 1173-1179.
27. Saino A, Pomidossi G, Perondi R, Morganti A, Turolo L, Mancia G. Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease. Circulation 2000;101:2277-2783.
28. Grassi G, Turri C, Seravalle G, Bertinieri G, Pierini A, Mancia G. Effects of chronic clonidine administration on sympathetic nerve traffic and baroreflex function in heart failure. Hypertension 2001;38:286-291.
29. Kirk JA, Kass DA. Electromechanical dyssynchrony and resynchronization of the failing heart. Circ Res 2013;113:765-776.
30. Grassi G, Vincenti A, Brambilla R, Trevano FQ, Dell'Oro R, Cirò A, Trocino G, Vincenzi A, Mancia G. Sustained sympathoinhibitory effects of cardiac resynchronization therapy in severe heart failure. Hypertension 2004;44:727-731.
31. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L. Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549.
32. Levy MN, Zieske H. Factorial analysis of the cardiovascular responses to carotid sinus nerve stimulation. Ann Biomed Eng 1976;4:111-127.
33. Chapleau MW, Hajduczok G, Abboud FM. Pulsatile activation of baroreceptors causes central facilitation of baroreflex. Am J Physiol 1989;256:H1735-H1741.
34. La Rovere MT, Pinna GD, Maestri R, Robbi E, Caporotondi A, Guazzotti G, Sleight P, Febo O. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J Am Coll Cardiol 2009;53:193-199.
35. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as marker of sympathetic activity. J Hypertens 1998;16:1635-1639.
36. Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation 1973;48:5-8.
37. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.